Two-Drug combo aims to keep deadly leukemia at bay after transplant

This study is testing whether a two-drug combination (blinatumomab and venetoclax) given as maintenance therapy after a stem cell transplant can help prevent leukemia from returning in high-risk patients. The trial involves 24 adults with a specific type of aggressive B-cell leukemia who have already received a donor stem cell transplant. Researchers will track patients for two years to see if this maintenance approach improves survival and reduces relapse rates while monitoring side effects.